Significant efforts have been made to find biomarkers that guide ICB therapy, such as programmed death-ligand-1 (PD-L1) expression, microsatellite instability (MSI)/mismatch-repair deficiency (dMMR), and tumor mutation burden 3-7. This evidence concerns the gene CD274 and neoplasm.